Isomorphic laboratory, AI drug discovery platform Rotate from Google’s Deepmind In 2021, external capital was raised for the first time. The $600 million round is led by GV Thrive Capital, from GV, the parent letter of existing investor Google, It says.
The funding will accelerate the isomorphic AI drug design engine and support the company’s goal of bringing the drugs it found into clinical trials.
The Isomorphic Laboratory was founded by Demis Hassabis, co-founder of DeepMind, which uses DeepMind’s software for AI drug discovery, including Alphafold, an AI model that predicts the three-dimensional structure of proteins.
Last year, Isomorph Labs established a strategic partnership with Eli Lilly and Novartis, possibly Generate up to $3 billion In the milestone payment for accessing their AI models.
Hassabis told The New York Times Although isomorphic labs do not require capital, additional funding will help the department hire top research scientists.
For their work on Alphafold, Hassabis and DeepMind researcher John Jumper are three accepted scientists Nobel Prize in Chemistry In 2024.
